LEXINGTON, Mass.–(BUSINESS WIRE)– AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that David Arkowitz, Executive Vice President, Chief Financial Officer and Chief Business Officer, and Lou Brenner, Senior Vice President, will present an overview of the Company at the Deutsche Bank 2009 Biotech Boston Confab Conference on December 15, 2009 at 12:30 p.m. ET. A live audio webcast of the presentation will be accessible through the Investors section of the Company’s website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until December 29, 2009. About AMAG Pharmaceuticals, Inc. AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. AMAG recently received approval from the U.S. Food and Drug Administration to market Feraheme (R) (ferumoxytol) Injection for the treatment of iron deficiency anemia in adult chronic kidney disease patients. For additional company and product information, please visit www.amagpharma.com. Feraheme(R) is a registered trademark of AMAG Pharmaceuticals, Inc.
Source: AMAG Pharmaceuticals, Inc.
Contact: AMAG Pharmaceuticals, Inc. Carol Miceli, 617-498-3361
As of November, 2020 AMAG Pharmaceuticals, Inc. is now a subsidiary of the Covis Pharma Group. For more information about Covis, please visit (covispharma.com)
